Smooth medication wearing off swings
- Trial ID
- NCT05916157
- Official Title
- A Post-marketing Observational Study for ABBV-951 in Patients Diagnosed With Advanced Parkinson's Disease (aPD)
- Goal
- Smooth medication wearing off swings
- Status
- RECRUITING
- Sponsor
- AbbVie
- Study Type
- OBSERVATIONAL
- Enrollment
- 250 participants
- Conditions
- Parkinson's Disease (PD)
Plain-Language Summary
The goal is to track how ABBV-951 performs in everyday care for people with advanced Parkinson's, looking at real-world safety, how well it reduces off time, and whether it helps daily function. ABBV-951 is a prescribed medication that provides continuous dopaminergic stimulation by activating dopamine receptors, used alongside levodopa to smooth out the on/off swings that happen as levodopa wears off. The study follows patients who are newly prescribed ABBV-951 by their doctor, includes people aged 15 and up with advanced PD who consent to participate, and excludes anyone who has already used ABBV-951 or is in another interventional trial.
Locations
- Saiseikai Matsuyama Hospital /ID# 276259, Matsuyama, Ehime, Japan
- National Hospital Organization Asahikawa Medical Center /ID# 269115, Asahikawa, Hokkaido, Japan
- Ryugasaki Saiseikai Hospital /ID# 264435, Ryūgasaki, Ibaraki, Japan
- University of Tsukuba Hospital /ID# 268353, Tsukuba, Ibaraki, Japan
- Okatsu Hospital /ID# 262781, Kagoshima, Kagoshima-ken, Japan
- University Hospital Kyoto Prefectural University of Medicine /ID# 267445, Kyoto, Kyoto, Japan
- Sendai Nishitaga National Hospital /ID# 268349, Sendai, Miyagi, Japan
- Fujimoto General Hospital /ID# 277287, Miyakonojo-shi, Miyazaki, Japan
- Shiga University of Medical Science Hospital /ID# 265637, Ōtsu, Shiga, Japan
- Dokkyo Medical University Hospital /ID# 269116, Mibu, Tochigi, Japan
- Juntendo University Hospital /ID# 264438, Bunkyo-ku, Tokyo, Japan
- Nitobe Memorial Nakano General Hospital /ID# 275668, Nakano-ku, Tokyo, Japan
- National Center of Neurology and Psychiatry - Kodaira /ID# 267372, Xiaoping City, Tokyo, Japan
- National Hospital Organization Utano Hospital /ID# 268350, Kyoto, Japan
- Okayama Neurology Clinic /ID# 269117, Okayama, Japan
- Municipal Toyonaka Hospital /ID# 271277, Toyonaka, Japan
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. The goal is to track how ABBV-951 performs in everyday care for people with advanced Parkinson's, looking at real-world safety, how well it reduces off time, and whether it helps daily function. ABBV-951 is a prescribed medication that provides continuous dopaminergic stimulation by activating dopamine receptors, used alongside levodopa to smooth out the on/off swings that happen as levodopa wears off. The study follows patients who are newly prescribed ABBV-951 by their doctor, includes people aged 15 and up with advanced PD who consent to participate, and excludes anyone who has already used ABBV-951 or is in another interventional trial.
- Who can participate?
- Participants must be at least 15 Years.
- Where is this trial located?
- This trial is recruiting at 16 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 7 months.